ANG1005 in Patients With Recurrent High-Grade Glioma
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in
patients with high-grade glioma. Another purpose of this study is to assess the efficacy,
safety, tolerability, and pharmacokinetics (PK) of ANG1005 in patients.